PHARMACOLOGICAL KINDLING
PHARMACOLOGICAL KINDLING
批准号:
5203745
负责人:
S R WEISS
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
aggression anticonvulsants atropine brain disorder chemotherapy carbamazepine chemoprevention cocaine corticotropin releasing factor dopamine drug administration rate /duration drug interactions drug screening /evaluation drug tolerance imipramine kindling laboratory rat lidocaine local anesthetics neuropharmacology neuroprotectants physostigmine procaine psychobiology psychopharmacology
中文摘要
本项目研究和操作的发展历程
使用局麻药利多卡因药理上点燃癫痫,
可卡因和普鲁卡因。除了癫痫发作,其他行为
研究异常,包括可卡因的行为刻板印象,
利多卡因和普鲁卡因的攻击和与可卡因有关的死亡率
癫痫发作。可卡因的点燃作用可能与其
局部麻醉剂的特性,与利多卡因的效果相似
普鲁卡因,但不能与其他精神运动兴奋剂配伍。它的重要性
关于人类可卡因滥用的局部麻醉机制的研究仍有待于
已确定,但与可卡因相关的恐慌症(这是
由50%的可卡因使用者报告的可卡因热线)类似
点燃癫痫的发展,从而提供了一个耐人寻味的临床基础
研究重叠。本项目的重大发现包括:1)
局麻药点燃癫痫及其相关因素的研究进展
死亡可以通过慢性,但不是急性或反复急性,
卡马西平治疗;2)局麻药点燃癫痫模型
可能为研究卡马西平的作用机制提供一种新的途径。
对情感性疾病采取行动,这也需要长期治疗;3)
卡马西平慢性治疗减轻可卡因诱导的多巴胺
伏隔核溢流,降低HVA水平;4)
系统α-2-肾上腺素能受体,外周型苯二氮
受体、5-羟色胺和生长抑素可以被排除为
卡马西平在癫痫发作中的抗惊厥作用
模型;5)应激相关肽促肾上腺皮质激素释放激素
(CRH)和三环抗抑郁药去甲基米帕明(DMI)
加强可卡因点燃癫痫的发展和致命性;6)普鲁卡因
点燃-癫痫类似于利多卡因癫痫-大鼠变成
在癫痫发作后表现出攻击性,他们可以持续多次发作
癫痫发作(与可卡因不同,在可卡因中有一两次癫痫发作经历
诱导致命性);慢性卡马西平似乎抑制
攻击,但不影响充分发展的癫痫发作;7)
胆碱能手法显著影响局麻药点燃
与普鲁卡因和可卡因相比,癫痫发作的发生和发展是不同的
为了利多卡因。阿托品阻断阿托品诱导的癫痫发作
增强后者诱导的癫痫发作。毒扁豆碱能使人衰弱
利多卡因点燃;8)采用普鲁卡因点燃模型,不同药物
评估给药方案的耐受性发展和
最佳预防措施。
英文摘要
This project studies and manipulates the course of development of
pharmacologically kindled seizures using the local anesthetics lidocaine,
cocaine, and procaine. In addition to seizures, other behavioral
abnormalities are studied, including behavioral stereotypys with cocaine,
aggression with lidocaine and procaine, and mortality related to cocaine
seizures. The kindling effects of cocaine are likely related to its
local anesthetic properties, as similar effects are seen with lidocaine
and procaine but not with other psychomotor stimulants. The importance
of local anesthetic mechanisms in human cocaine abuse remains to be
determined, but aspects of cocaine-related panic disorder (which is
reported by 50% of cocaine users calling a cocaine hotline) resemble
kindled seizure development, thus providing an intriguing clinical-basic
research overlap. Significant findings of this project include that: 1)
the development of local anesthetic-kindled seizures and their associated
lethality can be prevented with chronic, but not acute or repeated acute,
carbamazepine treatment; 2) the local anesthetic-kindled seizure model
may offer a novel approach to examining carbamazepine's mechanisms of
action in affective illness, which also requires chronic treatment; 3)
chronic treatment with carbamazepine attenuates cocaine-induced dopamine
overflow in the nucleus accumbens and decreases HVA levels; 4) the
systems alpha-2-adrenergic receptors, peripheral-type benzodiazepine
receptors, serotonin, and somatostatin can be ruled out as being
necessary to carbamazepine's anticonvulsant effects in this seizure
model; 5) the stress- related peptide corticotropin releasing hormone
(CRH) and the tricyclic antidepressant desmethylimipramine (DMI)
potentiate cocaine kindled seizure development and lethality; 6) procaine
kindled-seizures are similar to lidocaine seizures - rats become
aggressive after seizures develop, and they can sustain numerous bouts
of seizures (unlike with cocaine, in which one or two seizure experiences
induces lethality); chronic carbamazepine appears to inhibit the
aggression while not affecting the fully developed seizures; 7)
cholinergic manipulations markedly affect local anesthetic-kindled
seizure development and are distinct for procaine and cocaine compared
to lidocaine. Atropine blocks seizures induced by the former and
potentiates seizures induced by the latter. Physostigmine attenuates
lidocaine kindling; 8) Using the procaine kindling model, different drug
administration regimens were evaluated for tolerance development and
optimal prophylaxis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BEHAVIORAL SENSITIZATION
-
批准号:2578747
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
CONTINGENT INEFFICACY AND CONTINGENT TOLERANCE
-
批准号:5203747
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
PHARMACOLOGICAL KINDLING
-
批准号:3845320
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
PHARMACOLOGICAL KINDLING
-
批准号:3881014
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
CONTINGENT INEFFICACY AND CONTINGENT TOLERANCE
-
批准号:3781442
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
PHARMACOLOGICAL KINDLING
-
批准号:3781440
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
BEHAVIORAL SENSITIZATION
-
批准号:3759456
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
CONTINGENT INEFFICACY AND CONTINGENT TOLERANCE
-
批准号:3759459
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF AMYGDALA KINDLING
-
批准号:5203746
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
CONNTINGENT INEFFICACY AND CONTINGENT TOLERANCE
-
批准号:3881016
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF AMYGDALA KINDLING
-
批准号:3881015
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
CONTINGENT INEFFICACY AND CONTINGENT TOLERANCE
-
批准号:3845322
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF AMYGDALA KINDLING
-
批准号:3759458
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF AMYGDALA KINDLING
-
批准号:3781441
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
BEHAVIORAL SENSITIZATION
-
批准号:3781439
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
PHARMACOLOGICAL AND BIOCHEMICAL STUDIES OF AMYGDALA KINDLING
-
批准号:3845321
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
BEHAVIORAL SENSITIZATION
-
批准号:3845319
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
CONTINGENT INEFFICACY AND CONTINGENT TOLERANCE
-
批准号:2578750
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
BEHAVIORAL EFFECTS OF TRH
-
批准号:2449816
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
BEHAVIORAL SENSITIZATION
-
批准号:5203744
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:S R WEISS
-
依托单位:
海外基金